Author:
Concannon C G,Koehler B F,Reimertz Claus,Murphy B M,Bonner C,Thurow N,Ward M W,Villunger A,Strasser A,Kögel D,Prehn J H M
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference56 articles.
1. Adams J . (2002). Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 14: 628–634.
2. Adams J . (2004a). The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349.
3. Adams J . (2004b). The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349–360.
4. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ et al. (2002). A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8: 2505–2511.
5. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A . (2004). Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 64: 4912–4918.
Cited by
87 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献